TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07218523: A Phase 3, Multicentre, Randomised (1:1), Parallel-group, Active-controlled, Central Reader Colonoscopist-blind Study to Evaluate the Bowel Cleansing Efficacy, Safety, Tolerability, Palatability, and Acceptability of PLE

Sponsor: Norgine · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 212 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,940,144

Rescue Site Savings

+$3,912,952

Unlock Full NCT07218523 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07218523 Rescue Dossier →